ClinicalTrials.gg
CompletedNCT02942017Updated Sep 15, 2025Results posted

A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)

A Phase 3 interventional study of Placebo and SAGE-547 90 μg/kg/h in Postpartum Depression, sponsored by Supernus Pharmaceuticals, Inc.. Completed at 32 sites in United States. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-09-15.

Sponsored by Supernus Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 220 studies in Depression, Postpartum with a site in United States — 38 open to participants now, 49 under way, 3 of them phase 3. Depression, Postpartum · United States.

Enrollment
84th of 198
108 · median 86
Started
2016
with 8 others
Phase 3
12 of 220
1 open now
Registered
79th of 220
by date
Lead sponsor
6 of 220
Supernus Pharmaceuticals, Inc.

Among the 220 studies in Depression, Postpartum with a site in United States, this one is the 84th largest by enrollment of the 198 interventional ones that give a count, is one of 9 that started in 2016, is one of 12 in phase 3, and was the 79th registered.

Depression, Postpartum

569 studies on the registry are indexed under Depression, Postpartum; 134 are open to participants now.

Browse Depression, Postpartum studies →

Open to participants now

38 of the 220 studies in Depression, Postpartum with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 87 Depression, Postpartum studies recruiting now, 54 (62%) set no upper age limit and 30 (34%) stop at 75 or younger; 13 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 220 studies in Depression, Postpartum with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study was to determine if SAGE-547 Injection infused intravenously at up to 90 μg/kg/h for 60 hours reduces depressive symptoms in participants with moderate postpartum depression (PPD) compared to placebo injection as assessed by the change from baseline in Hamilton Rating Scale for Depression (HAM-D) total score.

03

Conditions studied

  • Postpartum Depression

Keywords

  • Moderate Postpartum Depression
  • SAGE-547
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participant either must have ceased lactating at screening; or if still lactating or actively breastfeeding at screening, agreed to temporarily cease giving breastmilk to their infant(s).
  • Participant had a major depressive episode that began no earlier than the third trimester and no later than the first 4 weeks following delivery, as diagnosed by Structured Clinical Interview for Axis I Disorders (SCID-I).
  • Participant had a HAM-D total score of ≥20 and ≤25 at screening and Day 1 (prior to dosing).
  • Participant was ≤ six months postpartum.
  • Participant was amenable to intravenous therapy.

Key Exclusion Criteria:

  • Active psychosis.
  • Attempted suicide associated with index case of postpartum depression.
  • Medical history of bipolar disorder.

Note: Other protocol-defined inclusion/exclusion criteria applied.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
108 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received an infusion rate equivalent to the 90 micrograms per kilogram per hour (μg/kg/h) group.

    Drug: Placebo

  • Experimental
    SAGE-547 90 μg/kg/h

    Participants received a 4-hour dose titration period of 30 μg/kg/h (0 to 4 hours), then 60 μg/kg/h (4 to 24 hours), then 90 μg/kg/h (24 to 52 hours), followed by a taper to 60 μg/kg/h (52 to 56 hours), and 30 μg/kg/h (56 to 60 hours).

    Drug: SAGE-547 90 μg/kg/h

Interventions

  • DrugPlacebo

    Intravenous infusion of matching placebo for SAGE-547.

  • DrugSAGE-547 90 μg/kg/h

    Drug page: Brexanolone

    Intravenous infusion of SAGE-547

06

What researchers measure

Primary outcomes

  1. Change From Baseline at 60 Hours in 17-Item Hamilton Rating Scale for Depression (HAM-D) Total Score

    The HAM-D Total Score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The Total Score can range from 0 to 52, and higher scores indicate a greater degree of depression. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.

    Time frame: Baseline, Hour 60

Secondary outcomes

  1. Change From Baseline in HAM-D Total Score at Day 30

    The HAM-D Total Score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The Total Score can range from 0 to 52, and higher scores indicate a greater degree of depression. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.

    Time frame: Baseline, Day 30

  2. Change From Baseline in HAM-D Total Score

    The HAM-D Total Score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The Total Score can range from 0 to 52, and higher scores indicate a greater degree of depression. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.

    Time frame: Baseline, Hours 2, 4, 8, 12, 24, 36, 48, 72, and Days 7, 14 and 21

  3. Percentage of Participants With HAM-D Response

    The HAM-D response is defined as having a 50% or greater reduction from baseline in HAM-D total score. The HAM-D Total Score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The Total Score can range from 0 to 52, and higher scores indicate a greater degree of depression. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.

    Time frame: Hour 60, Days 7 and 30

  4. Percentage of Participants With HAM-D Remission

    HAM-D remission is defined as having a HAM-D total score of ≤7. The HAM-D Total Score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The Total Score can range from 0 to 52, and higher scores indicate a greater degree of depression. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.

    Time frame: Hour 60, Days 7 and 30

  5. Change From Baseline in HAM-D Bech 6 Subscale

    The HAM-D Bech 6 subscale score is calculated as the sum of the following six items: Item # 1 (depressed mood), Item # 2 (feelings of guilt), Item # 7 (work and activities), Item # 8 (retardation), Item # 10 (anxiety psychic), and Item # 13 (general somatic symptoms). Each item is scored in a range of 0 to 2 or 0 to 4, with higher scores indicating a greater degree of depression. The scores were transformed to a 100-point scale with a higher score indicating a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.

    Time frame: Baseline, Hour 60, Days 7 and 30

  6. Change From Baseline in HAM-D Individual Item Scores

    The HAM-D comprises individual ratings of the following symptoms scored in a range of 0 to 2: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following symptoms are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.

    Time frame: Baseline, Hours 2, 4, 8, 12, 24, 36, 48, 60, 72, and Days 7, 14, 21, and 30

  7. Change From Baseline at Key Time Points in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score

    The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in participants with mood disorders. It was designed as an adjunct to the HAM-D, to be more sensitive than the Hamilton Scale to the changes brought on by antidepressants and other forms of treatment. Each item yielded a score of 0 to 6. The MADRS total score was calculated as the sum of the 10 individual item scores, which ranged from 0 to 60. Higher MADRS scores indicates more severe depression. A negative change from baseline indicates less severe depression. A positive change from baseline indicates more severe depression.

    Time frame: Baseline, Hour 60, Days 7 and 30

  8. Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Response

    The CGI-I response was defined as having a score of 1 (very much improved) or 2 (much improved). CGI-I item employs a 7-point Likert scale to measure the overall improvement in the participant's condition post-treatment. The investigator rated the participant's total improvement whether or not it was due entirely to drug treatment. Response choices include: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. The CGI-I was only rated at post-treatment assessments. By definition, all CGI-I assessments were evaluated against baseline conditions.

    Time frame: Hour 60, Days 7 and 30

  9. Change From Baseline in the Generalized Anxiety Disorder 7-Item Scale (GAD-7) Total Score

    The GAD-7 is a participant-rated, generalized anxiety symptom severity scale. Scoring for GAD-7 generalized anxiety is calculated by assigning scores of 0 = "not at all sure," 1 = "several days," 2 = "over half the days," and 3 = "nearly every day" to the response categories. The GAD-7 total score for the seven items ranges from 0 to 21, where a score of 0 to 4 = minimal anxiety, 5 to 9 = mild anxiety, 10 to 14 = moderate anxiety, and 15 to 21 = severe anxiety. The GAD-7 total score was calculated as the sum of the seven individual item scores. A negative change from baseline indicates less anxiety. A positive change from baseline indicates more anxiety.

    Time frame: Baseline, Hour 60, Days 7, 14, 21 and 30

  10. Percentage of Participants With Treatment Emergent Adverse Event (TEAE)

    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an AE with onset on or after the start of study drug infusion, or any worsening of a pre-existing medical condition/AE with onset on or after the start of study drug infusion.

    Time frame: Up to approximately 37 days

  11. Time to Change in Antidepressant Medication

    The time to first start or increase in the dose and time to first stop or decrease in the dose of any antidepressant medication.

    Time frame: Up to approximately 37 days

07

Results

Posted Jun 13, 2019

Participant flow

Participants took part in the study at 32 centers in United States from 25 July 2016 to 11 October 2017.

Participant flow — Overall Study
MilestonePlaceboSAGE-547 90 μg/kg/h
Started5454
Treated5351
Completed5248
Not completed26
Withdrew: Adverse event01
Withdrew: Withdrawal by subject01
Withdrew: Lost to follow-up11
Withdrew: Randomized but not dosed13

Outcome measures

PrimaryChange From Baseline at 60 Hours in 17-Item Hamilton Rating Scale for Depression (HAM-D) Total Score

The HAM-D Total Score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The Total Score can range from 0 to 52, and higher scores indicate a greater degree of depression. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.

Time frame:
Baseline, Hour 60
Reported as:
Least squares mean · score on a scale
Change From Baseline at 60 Hours in 17-Item Hamilton Rating Scale for Depression (HAM-D) Total Score
score on a scalePlaceboSAGE-547 90 μg/kg/h
Change From Baseline at 60 Hours in 17-Item Hamilton Rating Scale for Depression (HAM-D) Total Score-12.12 ± 0.773-14.62 ± 0.782
Statistical analysis
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0160 · Least square (ls) mean difference: -2.50 · 95% CI -4.52 to -0.48
SecondaryChange From Baseline in HAM-D Total Score at Day 30

The HAM-D Total Score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The Total Score can range from 0 to 52, and higher scores indicate a greater degree of depression. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.

Time frame:
Baseline, Day 30
Reported as:
Least squares mean · score on a scale
Change From Baseline in HAM-D Total Score at Day 30
score on a scalePlaceboSAGE-547 90 μg/kg/h
Change From Baseline in HAM-D Total Score at Day 30-15.23 ± 0.934-14.69 ± 0.955
Statistical analysis
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.6710 · Ls mean difference: 0.54 · 95% CI -1.98 to 3.07
SecondaryChange From Baseline in HAM-D Total Score

The HAM-D Total Score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The Total Score can range from 0 to 52, and higher scores indicate a greater degree of depression. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.

Time frame:
Baseline, Hours 2, 4, 8, 12, 24, 36, 48, 72, and Days 7, 14 and 21
Reported as:
Least squares mean · score on a scale
Change From Baseline in HAM-D Total Score
score on a scalePlaceboSAGE-547 90 μg/kg/h
Change at Hour 2-4.00 ± 0.598-4.60 ± 0.595
Change at Hour 4-6.55 ± 0.701-7.32 ± 0.702
Change at Hour 8-7.44 ± 0.738-8.38 ± 0.740
Change at Hour 12-7.96 ± 0.758-9.10 ± 0.762
Change at Hour 24-9.81 ± 0.820-11.42 ± 0.827
Change at Hour 36-10.45 ± 0.833-12.31 ± 0.843
Change at Hour 48-10.59 ± 0.860-13.00 ± 0.873
Change at Hour 72-11.83 ± 0.829-15.31 ± 0.841
Change at Day 7-10.74 ± 1.042-13.98 ± 1.061
Change at Day 14-11.40 ± 0.989-13.43 ± 1.013
Change at Day 21-13.26 ± 1.022-13.59 ± 1.041
Statistical analysis
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.4216 · Ls mean difference: -0.60 · 95% CI -2.06 to 0.87
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.3947 · Ls mean difference: -0.77 · 95% CI -2.57 to 1.02
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.3280 · Ls mean difference: -0.95 · 95% CI -2.86 to 0.96
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.2522 · Ls mean difference: -1.14 · 95% CI -3.12 to 0.83
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.1431 · Ls mean difference: -1.61 · 95% CI -3.78 to 0.55
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0991 · Ls mean difference: -1.85 · 95% CI -4.06 to 0.36
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0389 · Ls mean difference: -2.42 · 95% CI -4.71 to -0.13
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0022 · Ls mean difference: -3.48 · 95% CI -5.67 to -1.28
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0255 · Ls mean difference: -3.24 · 95% CI -6.08 to -0.40
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.1375 · Ls mean difference: -2.03 · 95% CI -4.73 to 0.66
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.8170 · Ls mean difference: -0.33 · 95% CI -3.11 to 2.46
SecondaryPercentage of Participants With HAM-D Response

The HAM-D response is defined as having a 50% or greater reduction from baseline in HAM-D total score. The HAM-D Total Score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The Total Score can range from 0 to 52, and higher scores indicate a greater degree of depression. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.

Time frame:
Hour 60, Days 7 and 30
Reported as:
Number · percentage of participants
Percentage of Participants With HAM-D Response
percentage of participantsPlaceboSAGE-547 90 μg/kg/h
Hour 6059.675.5
Day 750.966.0
Day 3078.870.8
Statistical analysis
  • Placebo vs SAGE-547 90 μg/kg/h · GEE method · p = 0.0168 · Odds ratio (or): 2.9 · 95% CI 1.2 to 6.7
  • Placebo vs SAGE-547 90 μg/kg/h · GEE method · p = 0.0482 · Odds ratio (or): 2.6 · 95% CI 1.0 to 6.6
  • Placebo vs SAGE-547 90 μg/kg/h · GEE method · p = 0.5857 · Odds ratio (or): 0.8 · 95% CI 0.3 to 2.0
SecondaryPercentage of Participants With HAM-D Remission

HAM-D remission is defined as having a HAM-D total score of ≤7. The HAM-D Total Score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The Total Score can range from 0 to 52, and higher scores indicate a greater degree of depression. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.

Time frame:
Hour 60, Days 7 and 30
Reported as:
Number · percentage of participants
Percentage of Participants With HAM-D Remission
percentage of participantsPlaceboSAGE-547 90 μg/kg/h
Hour 6038.561.2
Day 732.156.0
Day 3061.547.9
Statistical analysis
  • Placebo vs SAGE-547 90 μg/kg/h · GEE method · p = 0.0033 (Hour 60:) · Odds ratio (or): 3.4 · 95% CI 1.5 to 7.9
  • Placebo vs SAGE-547 90 μg/kg/h · GEE method · p = 0.0046 · Odds ratio (or): 3.7 · 95% CI 1.5 to 9.3
  • Placebo vs SAGE-547 90 μg/kg/h · GEE method · p = 0.3085 · Odds ratio (or): 0.6 · 95% CI 0.3 to 1.5
SecondaryChange From Baseline in HAM-D Bech 6 Subscale

The HAM-D Bech 6 subscale score is calculated as the sum of the following six items: Item # 1 (depressed mood), Item # 2 (feelings of guilt), Item # 7 (work and activities), Item # 8 (retardation), Item # 10 (anxiety psychic), and Item # 13 (general somatic symptoms). Each item is scored in a range of 0 to 2 or 0 to 4, with higher scores indicating a greater degree of depression. The scores were transformed to a 100-point scale with a higher score indicating a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.

Time frame:
Baseline, Hour 60, Days 7 and 30
Reported as:
Least squares mean · score on a scale
Change From Baseline in HAM-D Bech 6 Subscale
score on a scalePlaceboSAGE-547 90 μg/kg/h
Change at Hour 60-29.23 ± 2.248-37.59 ± 2.276
Change at Day 7-25.05 ± 2.624-34.80 ± 2.668
Change at Day 30-36.24 ± 2.345-34.86 ± 2.390
Statistical analysis
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0063 · Ls mean difference: -8.35 · 95% CI -14.29 to -2.42
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0074 · Ls mean difference: -9.75 · 95% CI -16.83 to -2.68
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.6637 · Ls mean difference: 1.37 · 95% CI -4.88 to 7.63
SecondaryChange From Baseline in HAM-D Individual Item Scores

The HAM-D comprises individual ratings of the following symptoms scored in a range of 0 to 2: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following symptoms are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.

Time frame:
Baseline, Hours 2, 4, 8, 12, 24, 36, 48, 60, 72, and Days 7, 14, 21, and 30
Reported as:
Least squares mean · score on a scale
Change From Baseline in HAM-D Individual Item Scores
score on a scalePlaceboSAGE-547 90 μg/kg/h
Depressed Mood, Change at Hour 2-0.35 ± 0.121-0.45 ± 0.121
Depressed Mood, Change at Hour 4-0.67 ± 0.137-0.92 ± 0.138
Depressed Mood, Change at Hour 8-0.90 ± 0.136-1.20 ± 0.136
Depressed Mood, Change at Hour 12-1.05 ± 0.139-1.18 ± 0.140
Depressed Mood, Change at Hour 24-1.01 ± 0.143-1.34 ± 0.145
Depressed Mood, Change at Hour 36-1.35 ± 0.145-1.64 ± 0.147
Depressed Mood, Change at Hour 48-1.33 ± 0.144-1.74 ± 0.146
Depressed Mood, Change at Hour 60-1.62 ± 0.142-1.91 ± 0.144
Depressed Mood, Change at Hour 72-1.63 ± 0.137-1.93 ± 0.140
Depressed Mood, Change at Day 7-1.43 ± 0.159-1.82 ± 0.161
Depressed Mood, Change at Day 14-1.42 ± 0.170-1.59 ± 0.174
Depressed Mood, Change at Day 21-1.80 ± 0.168-1.56 ± 0.170
Depressed Mood, Change at Day 30-2.07 ± 0.137-1.89 ± 0.140
Feelings of Guilt, Change at Hour 2-0.37 ± 0.125-0.59 ± 0.125
Feelings of Guilt, Change at Hour 4-0.56 ± 0.127-1.00 ± 0.127
Feelings of Guilt, Change at Hour 8-0.81 ± 0.124-1.04 ± 0.124
Feelings of Guilt, Change at Hour 12-0.69 ± 0.127-0.98 ± 0.128
Feelings of Guilt, Change at Hour 24-0.86 ± 0.122-1.16 ± 0.123
Feelings of Guilt, Change at Hour 36-0.75 ± 0.127-1.09 ± 0.129
Feelings of Guilt, Change at Hour 48-0.90 ± 0.129-1.11 ± 0.131
Feelings of Guilt, Change at Hour 60-0.99 ± 0.119-1.28 ± 0.120
Feelings of Guilt, Change at Hour 72-0.94 ± 0.121-1.34 ± 0.123
Feelings of Guilt, Change at Day 7-0.82 ± 0.135-1.14 ± 0.137
Feelings of Guilt, Change at Day 14-0.90 ± 0.133-1.00 ± 0.136
Feelings of Guilt, Change at Day 21-1.01 ± 0.126-1.11 ± 0.128
Feelings of Guilt, Change at Day 30-1.31 ± 0.111-1.20 ± 0.112
Suicide, Change at Hour 2-0.11 ± 0.062-0.19 ± 0.062
Suicide, Change at Hour 4-0.20 ± 0.062-0.28 ± 0.062
Suicide, Change at Hour 8-0.26 ± 0.062-0.32 ± 0.062
Suicide, Change at Hour 12-0.27 ± 0.062-0.36 ± 0.062
Suicide, Change at Hour 24-0.31 ± 0.062-0.38 ± 0.062
Suicide, Change at Hour 36-0.29 ± 0.062-0.38 ± 0.063
Suicide, Change at Hour 48-0.29 ± 0.062-0.40 ± 0.063
Suicide, Change at Hour 60-0.33 ± 0.062-0.40 ± 0.063
Suicide, Change at Hour 72-0.33 ± 0.062-0.40 ± 0.063
Suicide, Change at Day 7-0.29 ± 0.062-0.30 ± 0.062
Suicide, Change at Day 14-0.35 ± 0.068-0.32 ± 0.069
Suicide, Change at Day 21-0.36 ± 0.068-0.36 ± 0.068
Suicide, Change at Day 30-0.37 ± 0.062-0.38 ± 0.063
Insomnia - Early, Change at Hour 2-0.18 ± 0.077-0.22 ± 0.077
Insomnia - Early, Change at Hour 4-0.35 ± 0.092-0.26 ± 0.092
Insomnia - Early, Change at Hour 8-0.28 ± 0.085-0.26 ± 0.085
Insomnia - Early, Change at Hour 12-0.36 ± 0.090-0.25 ± 0.091
Insomnia - Early, Change at Hour 24-0.54 ± 0.111-0.81 ± 0.113
Insomnia - Early, Change at Hour 36-0.62 ± 0.115-0.80 ± 0.117
Insomnia - Early, Change at Hour 48-0.62 ± 0.122-0.94 ± 0.125
Insomnia - Early, Change at Hour 60-0.87 ± 0.130-0.96 ± 0.133
Insomnia - Early, Change at Hour 72-0.54 ± 0.119-0.93 ± 0.122
Insomnia - Early, Change at Day 7-0.69 ± 0.130-0.95 ± 0.133
Insomnia - Early, Change at Day 14-0.78 ± 0.142-0.98 ± 0.145
Insomnia - Early, Change at Day 21-0.98 ± 0.156-0.95 ± 0.157
Insomnia - Early, Change at Day 30-1.05 ± 0.126-0.96 ± 0.130
Insomnia - Middle, Change at Hour 2-0.18 ± 0.089-0.08 ± 0.089
Insomnia - Middle, Change at Hour 4-0.20 ± 0.092-0.22 ± 0.092
Insomnia - Middle, Change at Hour 8-0.28 ± 0.092-0.22 ± 0.092
Insomnia - Middle, Change at Hour 12-0.30 ± 0.094-0.15 ± 0.094
Insomnia - Middle, Change at Hour 24-0.52 ± 0.103-0.84 ± 0.105
Insomnia - Middle, Change at Hour 36-0.64 ± 0.103-0.91 ± 0.105
Insomnia - Middle, Change at Hour 48-0.58 ± 0.106-0.88 ± 0.109
Insomnia - Middle, Change at Hour 60-0.67 ± 0.099-0.96 ± 0.101
Insomnia - Middle, Change at Hour 72-0.77 ± 0.101-1.00 ± 0.103
Insomnia - Middle, Change at Day 7-0.67 ± 0.112-0.89 ± 0.114
Insomnia - Middle, Change at Day 14-0.62 ± 0.135-0.85 ± 0.137
Insomnia - Middle, Change at Day 21-0.81 ± 0.139-0.79 ± 0.138
Insomnia - Middle, Change at Day 30-0.84 ± 0.120-0.91 ± 0.123
Insomnia - Late, Change at Hour 2-0.14 ± 0.091-0.03 ± 0.092
Insomnia - Late, Change at Hour 4-0.20 ± 0.095-0.13 ± 0.096
Insomnia - Late, Change at Hour 8-0.20 ± 0.090-0.23 ± 0.090
Insomnia - Late, Change at Hour 12-0.21 ± 0.091-0.23 ± 0.092
Insomnia - Late, Change at Hour 24-0.54 ± 0.100-0.59 ± 0.101
Insomnia - Late, Change at Hour 36-0.46 ± 0.102-0.45 ± 0.105
Insomnia - Late, Change at Hour 48-0.56 ± 0.097-0.61 ± 0.100
Insomnia - Late, Change at Hour 60-0.60 ± 0.098-0.63 ± 0.100
Insomnia - Late, Change at Hour 72-0.50 ± 0.104-0.76 ± 0.107
Insomnia - Late, Change at Day 7-0.46 ± 0.100-0.64 ± 0.102
Insomnia - Late, Change at Day 14-0.27 ± 0.128-0.66 ± 0.130
Insomnia - Late, Change at Day 21-0.51 ± 0.125-0.64 ± 0.126
Insomnia - Late, Change at Day 30-0.67 ± 0.099-0.72 ± 0.101
Work and Activities, Change at Hour 2-0.26 ± 0.109-0.41 ± 0.109
Work and Activities, Change at Hour 4-0.73 ± 0.130-0.72 ± 0.131
Work and Activities, Change at Hour 8-0.77 ± 0.139-1.02 ± 0.141
Work and Activities, Change at Hour 12-1.07 ± 0.151-1.18 ± 0.152
Work and Activities, Change at Hour 24-1.34 ± 0.149-1.33 ± 0.151
Work and Activities, Change at Hour 36-1.54 ± 0.146-1.65 ± 0.149
Work and Activities, Change at Hour 48-1.45 ± 0.138-1.71 ± 0.141
Work and Activities, Change at Hour 60-1.60 ± 0.134-2.04 ± 0.136
Work and Activities, Change at Hour 72-1.68 ± 0.143-2.06 ± 0.146
Work and Activities, Change at Day 7-1.66 ± 0.157-1.94 ± 0.160
Work and Activities, Change at Day 14-1.40 ± 0.161-1.84 ± 0.165
Work and Activities, Change at Day 21-1.75 ± 0.174-1.70 ± 0.178
Work and Activities, Change at Day 30-2.04 ± 0.142-2.00 ± 0.145
Retardation, Change at Hour 2-0.03 ± 0.0880.06 ± 0.089
Retardation, Change at Hour 4-0.20 ± 0.0850.00 ± 0.086
Retardation, Change at Hour 8-0.25 ± 0.085-0.13 ± 0.086
Retardation, Change at Hour 12-0.27 ± 0.082-0.29 ± 0.083
Retardation, Change at Hour 24-0.18 ± 0.090-0.17 ± 0.092
Retardation, Change at Hour 36-0.35 ± 0.082-0.38 ± 0.084
Retardation, Change at Hour 48-0.35 ± 0.079-0.24 ± 0.081
Retardation, Change at Hour 60-0.46 ± 0.066-0.55 ± 0.068
Retardation, Change at Hour 72-0.48 ± 0.073-0.44 ± 0.075
Retardation, Change at Day 7-0.33 ± 0.073-0.55 ± 0.074
Retardation, Change at Day 14-0.47 ± 0.061-0.58 ± 0.060
Retardation, Change at Day 21-0.51 ± 0.070-0.57 ± 0.068
Retardation, Change at Day 30-0.54 ± 0.056-0.55 ± 0.058
Agitation, Change at Hour 2-0.27 ± 0.078-0.47 ± 0.078
Agitation, Change at Hour 4-0.42 ± 0.082-0.65 ± 0.082
Agitation, Change at Hour 8-0.40 ± 0.081-0.71 ± 0.081
Agitation, Change at Hour 12-0.32 ± 0.093-0.62 ± 0.094
Agitation, Change at Hour 24-0.52 ± 0.081-0.74 ± 0.083
Agitation, Change at Hour 36-0.40 ± 0.092-0.66 ± 0.094
Agitation, Change at Hour 48-0.44 ± 0.087-0.78 ± 0.089
Agitation, Change at Hour 60-0.42 ± 0.097-0.64 ± 0.099
Agitation, Change at Hour 72-0.37 ± 0.092-0.74 ± 0.094
Agitation, Change at Day 7-0.39 ± 0.096-0.65 ± 0.097
Agitation, Change at Day 14-0.58 ± 0.107-0.67 ± 0.108
Agitation, Change at Day 21-0.56 ± 0.112-0.65 ± 0.114
Agitation, Change at Day 30-0.60 ± 0.075-0.73 ± 0.077
Anxiety Psychic, Change at Hour 2-0.45 ± 0.126-0.67 ± 0.126
Anxiety Psychic, Change at Hour 4-0.81 ± 0.138-0.93 ± 0.138
Anxiety Psychic, Change at Hour 8-0.89 ± 0.141-1.05 ± 0.142
Anxiety Psychic, Change at Hour 12-0.89 ± 0.143-1.01 ± 0.144
Anxiety Psychic, Change at Hour 24-1.00 ± 0.140-1.13 ± 0.141
Anxiety Psychic, Change at Hour 36-1.06 ± 0.141-1.20 ± 0.143
Anxiety Psychic, Change at Hour 48-0.92 ± 0.142-1.24 ± 0.144
Anxiety Psychic, Change at Hour 60-0.98 ± 0.131-1.51 ± 0.133
Anxiety Psychic, Change at Hour 72-1.08 ± 0.135-1.36 ± 0.137
Anxiety Psychic, Change at Day 7-0.70 ± 0.133-1.21 ± 0.134
Anxiety Psychic, Change at Day 14-0.76 ± 0.178-0.82 ± 0.184
Anxiety Psychic, Change at Day 21-0.94 ± 0.156-0.83 ± 0.158
Anxiety Psychic, Change at Day 30-1.25 ± 0.138-1.10 ± 0.141
Anxiety Somatic, Change at Hour 2-0.54 ± 0.100-0.61 ± 0.101
Anxiety Somatic, Change at Hour 4-0.71 ± 0.098-0.81 ± 0.099
Anxiety Somatic, Change at Hour 8-0.62 ± 0.102-0.69 ± 0.103
Anxiety Somatic, Change at Hour 12-0.60 ± 0.099-0.87 ± 0.100
Anxiety Somatic, Change at Hour 24-0.73 ± 0.103-0.77 ± 0.105
Anxiety Somatic, Change at Hour 36-0.75 ± 0.098-0.89 ± 0.100
Anxiety Somatic, Change at Hour 48-0.79 ± 0.100-0.96 ± 0.103
Anxiety Somatic, Change at Hour 60-0.88 ± 0.101-0.95 ± 0.104
Anxiety Somatic, Change at Hour 72-0.84 ± 0.088-1.08 ± 0.090
Anxiety Somatic, Change at Day 7-0.66 ± 0.112-0.92 ± 0.114
Anxiety Somatic, Change at Day 14-0.85 ± 0.139-0.63 ± 0.139
Anxiety Somatic, Change at Day 21-0.90 ± 0.119-1.01 ± 0.118
Anxiety Somatic, Change at Day 30-0.88 ± 0.110-0.97 ± 0.113
Somatic Symptoms GI, Change at Hour 2-0.22 ± 0.091-0.15 ± 0.092
Somatic Symptoms GI, Change at Hour 4-0.33 ± 0.096-0.39 ± 0.096
Somatic Symptoms GI, Change at Hour 8-0.56 ± 0.087-0.37 ± 0.087
Somatic Symptoms GI, Change at Hour 12-0.56 ± 0.090-0.45 ± 0.091
Somatic Symptoms GI, Change at Hour 24-0.48 ± 0.083-0.54 ± 0.084
Somatic Symptoms GI, Change at Hour 36-0.60 ± 0.084-0.51 ± 0.086
Somatic Symptoms GI, Change at Hour 48-0.56 ± 0.086-0.59 ± 0.088
Somatic Symptoms GI, Change at Hour 60-0.73 ± 0.091-0.71 ± 0.093
Somatic Symptoms GI, Change at Hour 72-0.77 ± 0.081-0.75 ± 0.082
Somatic Symptoms GI, Change at Day 7-0.47 ± 0.093-0.67 ± 0.095
Somatic Symptoms GI, Change at Day 14-0.64 ± 0.093-0.79 ± 0.094
Somatic Symptoms GI, Change at Day 21-0.61 ± 0.107-0.83 ± 0.108
Somatic Symptoms GI, Change at Day 30-0.77 ± 0.085-0.73 ± 0.087
Somatic Symptoms General, Change at Hour 2-0.18 ± 0.081-0.15 ± 0.079
Somatic Symptoms General, Change at Hour 4-0.29 ± 0.095-0.35 ± 0.094
Somatic Symptoms General, Change at Hour 8-0.38 ± 0.094-0.45 ± 0.093
Somatic Symptoms General, Change at Hour 12-0.50 ± 0.094-0.75 ± 0.093
Somatic Symptoms General, Change at Hour 24-0.65 ± 0.104-0.73 ± 0.104
Somatic Symptoms General, Change at Hour 36-0.55 ± 0.097-0.69 ± 0.098
Somatic Symptoms General, Change at Hour 48-0.61 ± 0.101-0.69 ± 0.102
Somatic Symptoms General, Change at Hour 60-0.79 ± 0.105-0.91 ± 0.105
Somatic Symptoms General, Change at Hour 72-0.80 ± 0.112-1.05 ± 0.113
Somatic Symptoms General, Change at Day 7-0.57 ± 0.102-0.93 ± 0.103
Somatic Symptoms General, Change at Day 14-0.66 ± 0.118-0.94 ± 0.118
Somatic Symptoms General, Change at Day 21-0.82 ± 0.124-0.67 ± 0.123
Somatic Symptoms General, Change at Day 30-0.77 ± 0.104-0.86 ± 0.106
Genital Symptoms, Change at Hour 2-0.05 ± 0.0520.07 ± 0.053
Genital Symptoms, Change at Hour 4-0.09 ± 0.065-0.01 ± 0.066
Genital Symptoms, Change at Hour 8-0.07 ± 0.070-0.03 ± 0.070
Genital Symptoms, Change at Hour 12-0.05 ± 0.083-0.09 ± 0.085
Genital Symptoms, Change at Hour 24-0.11 ± 0.089-0.13 ± 0.091
Genital Symptoms, Change at Hour 36-0.18 ± 0.091-0.31 ± 0.094
Genital Symptoms, Change at Hour 48-0.18 ± 0.092-0.39 ± 0.095
Genital Symptoms, Change at Hour 60-0.23 ± 0.084-0.37 ± 0.086
Genital Symptoms, Change at Hour 72-0.22 ± 0.102-0.59 ± 0.105
Genital Symptoms, Change at Day 7-0.52 ± 0.112-0.57 ± 0.115
Genital Symptoms, Change at Day 14-0.56 ± 0.149-0.66 ± 0.152
Genital Symptoms, Change at Day 21-0.67 ± 0.147-0.76 ± 0.149
Genital Symptoms, Change at Day 30-0.84 ± 0.131-0.62 ± 0.135
Hypochondriasis, Change at Hour 2-0.14 ± 0.077-0.30 ± 0.077
Hypochondriasis, Change at Hour 4-0.20 ± 0.071-0.28 ± 0.071
Hypochondriasis, Change at Hour 8-0.22 ± 0.073-0.26 ± 0.073
Hypochondriasis, Change at Hour 12-0.18 ± 0.076-0.34 ± 0.076
Hypochondriasis, Change at Hour 24-0.37 ± 0.069-0.32 ± 0.069
Hypochondriasis, Change at Hour 36-0.25 ± 0.079-0.30 ± 0.080
Hypochondriasis, Change at Hour 48-0.35 ± 0.075-0.30 ± 0.076
Hypochondriasis, Change at Hour 60-0.29 ± 0.075-0.34 ± 0.075
Hypochondriasis, Change at Hour 72-0.31 ± 0.077-0.36 ± 0.078
Hypochondriasis, Change at Day 7-0.25 ± 0.088-0.27 ± 0.089
Hypochondriasis, Change at Day 14-0.14 ± 0.102-0.33 ± 0.104
Hypochondriasis, Change at Day 21-0.30 ± 0.093-0.35 ± 0.094
Hypochondriasis, Change at Day 30-0.31 ± 0.069-0.40 ± 0.070
Loss of Weight, Change at Hour 2-0.11 ± 0.055-0.06 ± 0.055
Loss of Weight, Change at Hour 4-0.17 ± 0.063-0.02 ± 0.063
Loss of Weight, Change at Hour 8-0.19 ± 0.053-0.08 ± 0.053
Loss of Weight, Change at Hour 12-0.21 ± 0.067-0.02 ± 0.067
Loss of Weight, Change at Hour 24-0.25 ± 0.067-0.04 ± 0.067
Loss of Weight, Change at Hour 36-0.23 ± 0.066-0.15 ± 0.067
Loss of Weight, Change at Hour 48-0.23 ± 0.074-0.11 ± 0.076
Loss of Weight, Change at Hour 60-0.19 ± 0.065-0.19 ± 0.065
Loss of Weight, Change at Hour 72-0.15 ± 0.076-0.23 ± 0.078
Loss of Weight, Change at Day 7-0.38 ± 0.091-0.18 ± 0.093
Loss of Weight, Change at Day 14-0.44 ± 0.125-0.39 ± 0.127
Loss of Weight, Change at Day 21-0.38 ± 0.130-0.50 ± 0.132
Loss of Weight, Change at Day 30-0.46 ± 0.111-0.42 ± 0.115
Insight, Change at Hour 20.01 ± 0.034-0.03 ± 0.034
Insight, Change at Hour 40.01 ± 0.034-0.05 ± 0.034
Insight, Change at Hour 80.05 ± 0.034-0.03 ± 0.034
Insight, Change at Hour 12-0.01 ± 0.034-0.03 ± 0.034
Insight, Change at Hour 240.01 ± 0.034-0.05 ± 0.034
Insight, Change at Hour 36-0.01 ± 0.034-0.01 ± 0.034
Insight, Change at Hour 48-0.01 ± 0.0340.01 ± 0.034
Insight, Change at Hour 60-0.04 ± 0.0340.01 ± 0.034
Insight, Change at Hour 72-0.01 ± 0.0340.01 ± 0.034
Insight, Change at Day 7-0.02 ± 0.034-0.07 ± 0.034
Insight, Change at Day 14-0.02 ± 0.038-0.02 ± 0.038
Insight, Change at Day 21-0.02 ± 0.038-0.02 ± 0.038
Insight, Change at Day 30-0.02 ± 0.034-0.01 ± 0.034
Statistical analysis
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.5132 · Ls mean difference: -0.10 · 95% CI -0.41 to 0.21
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.1672 · Ls mean difference: -0.25 · 95% CI -0.61 to 0.11
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0963 · Ls mean difference: -0.30 · 95% CI -0.65 to 0.05
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.4803 · Ls mean difference: -0.13 · 95% CI -0.49 to 0.23
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0844 · Ls mean difference: -0.33 · 95% CI -0.71 to 0.05
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.1325 · Ls mean difference: -0.29 · 95% CI -0.68 to 0.09
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0332 · Ls mean difference: -0.41 · 95% CI -0.79 to -0.03
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.1273 · Ls mean difference: -0.29 · 95% CI -0.67 to 0.08
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.1059 · Ls mean difference: -0.30 · 95% CI -0.66 to 0.06
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0683 · Ls mean difference: -0.40 · 95% CI -0.82 to 0.03
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.4458 · Ls mean difference: -0.18 · 95% CI -0.64 to 0.28
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.2905 · Ls mean difference: 0.24 · 95% CI -0.21 to 0.70
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.3096 · Ls mean difference: 0.19 · 95% CI -0.18 to 0.55
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.1925 · Ls mean difference: -0.22 · 95% CI -0.55 to 0.11
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0101 · Ls mean difference: -0.44 · 95% CI -0.77 to -0.11
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.1546 · Ls mean difference: -0.23 · 95% CI -0.56 to 0.09
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0901 · Ls mean difference: -0.29 · 95% CI -0.62 to 0.05
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0717 · Ls mean difference: -0.29 · 95% CI -0.62 to 0.03
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0468 · Ls mean difference: -0.34 · 95% CI -0.68 to 0.00
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.2222 · Ls mean difference: -0.21 · 95% CI -0.56 to 0.13
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0682 · Ls mean difference: -0.29 · 95% CI -0.60 to 0.02
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0147 · Ls mean difference: -0.40 · 95% CI -0.72 to -0.08
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0837 · Ls mean difference: -0.32 · 95% CI -0.68 to 0.04
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.5828 · Ls mean difference: -0.10 · 95% CI -0.46 to 0.26
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.5674 · Ls mean difference: -0.10 · 95% CI -0.43 to 0.24
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.4613 · Ls mean difference: 0.11 · 95% CI -0.18 to 0.40
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.3240 · Ls mean difference: -0.08 · 95% CI -0.24 to 0.08
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.3023 · Ls mean difference: -0.08 · 95% CI -0.24 to 0.08
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.4127 · Ls mean difference: -0.07 · 95% CI -0.23 to 0.09
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.2819 · Ls mean difference: -0.09 · 95% CI -0.25 to 0.07
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.3884 · Ls mean difference: -0.07 · 95% CI -0.23 to 0.09
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.2750 · Ls mean difference: -0.09 · 95% CI -0.25 to 0.07
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.1811 · Ls mean difference: -0.11 · 95% CI -0.27 to 0.05
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.3854 · Ls mean difference: -0.07 · 95% CI -0.23 to 0.09
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.3822 · Ls mean difference: -0.07 · 95% CI -0.23 to 0.09
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.9255 · Ls mean difference: -0.01 · 95% CI -0.17 to 0.15
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.6714 · Ls mean difference: 0.04 · 95% CI -0.14 to 0.22
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.9838 · Ls mean difference: 0.00 · 95% CI -0.18 to 0.18
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.8884 · Ls mean difference: -0.01 · 95% CI -0.17 to 0.15
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.6996 · Ls mean difference: -0.04 · 95% CI -0.23 to 0.16
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.4426 · Ls mean difference: 0.09 · 95% CI -0.15 to 0.33
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.8743 · Ls mean difference: 0.02 · 95% CI -0.20 to 0.24
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.3498 · Ls mean difference: 0.11 · 95% CI -0.12 to 0.35
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0839 · Ls mean difference: -0.26 · 95% CI -0.56 to 0.04
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.2595 · Ls mean difference: -0.18 · 95% CI -0.49 to 0.13
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0560 · Ls mean difference: -0.32 · 95% CI -0.66 to 0.01
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.6187 · Ls mean difference: -0.09 · 95% CI -0.45 to 0.27
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0187 · Ls mean difference: -0.39 · 95% CI -0.72 to -0.07
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.1531 · Ls mean difference: -0.26 · 95% CI -0.62 to 0.10
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.3341 · Ls mean difference: -0.19 · 95% CI -0.58 to 0.20
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.8969 · Ls mean difference: 0.03 · 95% CI -0.40 to 0.46
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.5862 · Ls mean difference: 0.10 · 95% CI -0.25 to 0.44
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.3776 · Ls mean difference: 0.10 · 95% CI -0.13 to 0.34
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.9029 · Ls mean difference: -0.01 · 95% CI -0.26 to 0.23
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.6173 · Ls mean difference: 0.06 · 95% CI -0.18 to 0.30
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.2433 · Ls mean difference: 0.15 · 95% CI -0.10 to 0.39
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0234 · Ls mean difference: -0.32 · 95% CI -0.59 to -0.04
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0540 · Ls mean difference: -0.27 · 95% CI -0.55 to 0.00
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0406 · Ls mean difference: -0.30 · 95% CI -0.58 to -0.01
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0295 · Ls mean difference: -0.29 · 95% CI -0.56 to -0.03
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0925 · Ls mean difference: -0.23 · 95% CI -0.50 to 0.04
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.1631 · Ls mean difference: -0.21 · 95% CI -0.52 to 0.09
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.2213 · Ls mean difference: -0.23 · 95% CI -0.60 to 0.14
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.9175 · Ls mean difference: 0.02 · 95% CI -0.36 to 0.39
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.6763 · Ls mean difference: -0.07 · 95% CI -0.40 to 0.26
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.3805 · Ls mean difference: 0.11 · 95% CI -0.13 to 0.35
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.6073 · Ls mean difference: 0.07 · 95% CI -0.19 to 0.32
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.7848 · Ls mean difference: -0.03 · 95% CI -0.27 to 0.20
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.9038 · Ls mean difference: -0.01 · 95% CI -0.25 to 0.23
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.6869 · Ls mean difference: 0.134 · 95% CI -0.32 to 0.21
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.9272 · Ls mean difference: 0.01 · 95% CI -0.26 to 0.29
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.6931 · Ls mean difference: -0.05 · 95% CI -0.31 to 0.21
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.8262 · Ls mean difference: -0.03 · 95% CI -0.29 to 0.23
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0749 · Ls mean difference: -0.25 · 95% CI -0.54 to 0.03
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.1923 · Ls mean difference: -0.18 · 95% CI -0.45 to 0.09
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0326 · Ls mean difference: -0.38 · 95% CI -0.73 to -0.03
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.4440 · Ls mean difference: -0.13 · 95% CI -0.47 to 0.21
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.7057 · Ls mean difference: -0.05 · 95% CI -0.32 to 0.22
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.2865 · Ls mean difference: -0.15 · 95% CI -0.42 to 0.13
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.9475 · Ls mean difference: 0.01 · 95% CI -0.33 to 0.35
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.1880 · Ls mean difference: -0.25 · 95% CI -0.61 to 0.12
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.5950 · Ls mean difference: -0.11 · 95% CI -0.51 to 0.29
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.9636 · Ls mean difference: 0.01 · 95% CI -0.39 to 0.41
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.5836 · Ls mean difference: -0.11 · 95% CI -0.50 to 0.28
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.1568 · Ls mean difference: -0.26 · 95% CI -0.63 to 0.10
  • Placebo vs SAGE-547 90 μg/kg/h · Wilcoxon (Mann-Whitney) · p = 0.0155 · Ls mean difference: -0.44 · 5% CI -0.79 to -0.09
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0504 · Ls mean difference: -0.38 · 95% CI -0.76 to 0.00
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.1865 · Ls mean difference: -0.28 · 95% CI -0.70 to 0.14
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0518 · Ls mean difference: -0.43 · 95% CI -0.87 to 0.00
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.8330 · Ls mean difference: 0.05 · 95% CI -0.42 to 0.53
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.8440 · Ls mean difference: 0.04 · 95% CI -0.34 to 0.42
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.4602 · Ls mean difference: 0.09 · 95% CI -0.15 to 0.33
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0891 · Ls mean difference: 0.20 · 95% CI -0.03 to 0.43
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.3088 · Ls mean difference: 0.12 · 95% CI -0.11 to 0.35
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.8560 · Ls mean difference: -0.02 · 95% CI -0.24 to 0.20
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.9702 · Ls mean difference: 0.00 · 95% CI -0.24 to 0.25
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.8001 · Ls mean difference: -0.03 · 95% CI -0.25 to 0.20
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.3223 · Ls mean difference: 0.11 · 95% CI -0.11 to 0.32
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.3385 · Ls mean difference: -0.09 · 95% CI -0.26 to 0.09
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.7003 · Ls mean difference: 0.04 · 95% CI -0.16 to 0.24
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0311 · Ls mean difference: -0.22 · 95% CI -0.41 to -0.02
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.1976 · Ls mean difference: -0.10 · 95% CI -0.26 to 0.06
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.5489 · Ls mean difference: -0.06 · 95% CI -0.24 to 0.13
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.7992 · Ls mean difference: -0.02 · 95% CI -0.17 to 0.13
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0573 · Ls mean difference: -0.20 · 95% CI -0.40 to 0.01
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0431 · Ls mean difference: -0.22 · 95% CI -0.44 to -0.01
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0060 · Ls mean difference: -0.30 · 95% CI -0.52 to -0.09
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0215 · Ls mean difference: -0.30 · 95% CI -0.55 to -0.04
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0422 · Ls mean difference: -0.22 · 95% CI -0.44 to -0.01
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0433 · Ls mean difference: -0.26 · 95% CI -0.51 to -0.01
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0051 · Ls mean difference: -0.34 · 95% CI -0.57 to -0.10
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0973 · Ls mean difference: -0.22 · 95% CI -0.48 to 0.04
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0036 · Ls mean difference: -0.38 · 95% CI -0.63 to -0.13
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0498 · Ls mean difference: -0.26 · 95% CI -0.52 to 0.00
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.5111 · Ls mean difference: -0.10 · 95% CI -0.39 to 0.20
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.5839 · Ls mean difference: -0.09 · 95% CI -0.39 to 0.22
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.1905 · Ls mean difference: -0.13 · 95% CI -0.33 to 0.07
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.1767 · Ls mean difference: -0.22 · 95% CI -0.54 to 0.10
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.5182 · Ls mean difference: -0.12 · 95% CI -0.47 to 0.24
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.3930 · Ls mean difference: -0.16 · 95% CI -0.53 to 0.21
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.5212 · Ls mean difference: -0.12 · 95% CI -0.50 to 0.25
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.4741 · Ls mean difference: -0.13 · 95% CI -0.50 to 0.23
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.4482 · Ls mean difference: -0.14 · 95% CI -0.51 to 0.23
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0963 · Ls mean difference: -0.31 · 95% CI -0.69 to 0.06
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0030 · Ls mean difference: -0.52 · 95% CI -0.86 to -0.18
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.1116 · Ls mean difference: -0.28 · 95% CI -0.63 to 0.07
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0040 · Ls mean difference: -0.51 · 95% CI -0.86 to -0.17
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.8253 · Ls mean difference: -0.05 · 95% CI -0.54 to 0.43
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.5795 · Ls mean difference: 0.12 · 95% CI -0.30 to 0.53
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.4032 · Ls mean difference: 0.15 · 95% CI -0.21 to 0.51
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.6117 · Ls mean difference: -0.07 · 95% CI -0.33 to 0.20
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.4716 · Ls mean difference: -0.09 · 95% CI -0.35 to 0.16
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.6041 · Ls mean difference: -0.07 · 95% CI -0.34 to 0.20
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0424 · Ls mean difference: -0.27 · 95% CI -0.53 to -0.01
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.7622 · Ls mean difference: -0.04 · 95% CI -0.32 to 0.23
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.2689 · Ls mean difference: -0.14 · 95% CI -0.40 to 0.11
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.2110 · Ls mean difference: -0.17 · 95% CI -0.44 to 0.10
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.5873 · Ls mean difference: -0.07 · 95% CI -0.34 to 0.20
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0450 · Ls mean difference: -0.23 · 95% CI -0.46 to -0.01
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0847 · Ls mean difference: -0.26 · 95% CI -0.57 to 0.04
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.2522 · Ls mean difference: 0.22 · 95% CI -0.16 to 0.60
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.5026 · Ls mean difference: -0.11 · 95% CI -0.43 to 0.21
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.5911 · Ls mean difference: -0.08 · 95% CI -0.38 to 0.22
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.5800 · Ls mean difference: 0.07 · 95% CI -0.18 to 0.31
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.6754 · Ls mean difference: -0.05 · 95% CI -0.31 to 0.20
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.1006 · Ls mean difference: 0.19 · 95% CI -0.04 to 0.42
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.3588 · Ls mean difference: 0.11 · 95% CI -0.13 to 0.35
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.5807 · Ls mean difference: -0.06 · 95% CI -0.28 to 0.16
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.4241 · Ls mean difference: 0.09 · 95% CI -0.13 to 0.31
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.7984 · Ls mean difference: -0.03 · 95% CI -0.26 to 0.20
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.8732 · Ls mean difference: 0.02 · 95% CI -0.22 to 0.26
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.8621 · Ls mean difference: 0.02 · 95% CI -0.19 to 0.23
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.1087 · Ls mean difference: -0.20 · 95% CI -0.45 to 0.05
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.2153 · Ls mean difference: -0.16 · 95% CI -0.41 to 0.09
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.1422 · Ls mean difference: -0.22 · 95% CI -0.51 to 0.07
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.7211 · Ls mean difference: 0.04 · 95% CI -0.19 to 0.27
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.8224 · Ls mean difference: 0.02 · 95% CI -0.18 to 0.23
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.6362 · Ls mean difference: -0.06 · 95% CI -0.31 to 0.19
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.6094 · Ls mean difference: -0.06 · 95% CI -0.31 to 0.18
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0457 · Ls mean difference: -0.25 · 95% CI -0.49 to 0.00
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.5691 · Ls mean difference: -0.08 · 95% CI -0.36 to 0.20
  • Placebo · MMRM · p = 0.2942 · Ls mean difference: -0.14 · 95% CI -0.40 to 0.12
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.5389 · Ls mean difference: -0.08 · 95% CI -0.35 to 0.19
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.4061 · Ls mean difference: -0.12 · 95% CI -0.40 to 0.16
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0990 · Ls mean difference: -0.25 · 95% CI -0.56 to 0.05
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0108 · Ls mean difference: -0.36 · 95% CI -0.63 to -0.08
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0889 · Ls mean difference: -0.28 · 95% CI -0.59 to 0.04
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.3721 · Ls mean difference: 0.15 · 95% CI -0.18 to 0.49
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.5513 · Ls mean difference: -0.08 · 95% CI -0.36 to 0.20
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0748 · Ls mean difference: 0.12 · 95% CI -0.01 to 0.26
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.3545 · Ls mean difference: 0.08 · 95% CI -0.09 to 0.25
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.6531 · Ls mean difference: 0.04 · 95% CI -0.14 to 0.23
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.7520 · Ls mean difference: -0.04 · 95% CI -0.26 to 0.19
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.8861 · Ls mean difference: -0.02 · 95% CI -0.26 to 0.23
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.3280 · Ls mean difference: -0.12 · 95% CI -0.38 to 0.13
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.1123 · Ls mean difference: -0.21 · 95% CI -0.46 to 0.05
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.2541 · Ls mean difference: -0.13 · 95% CI -0.36 to 0.10
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0110 · Ls mean difference: -0.37 · 95% CI -0.66 to -0.09
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.7720 · Ls mean difference: -0.05 · 95% CI -0.36 to 0.27
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.6311 · Ls mean difference: -0.10 · 95% CI -0.52 to 0.32
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.6877 · Ls mean difference: -0.08 · 95% CI -0.50 to 0.33
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.2465 · Ls mean difference: 0.22 · 95% CI -0.15 to 0.58
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.1279 · Ls mean difference: -0.16 · 95% CI -0.36 to 0.05
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.3946 · Ls mean difference: -0.08 · 95% CI -0.26 to 0.10
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.6694 · Ls mean difference: -0.04 · 95% CI -0.23 to 0.15
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.1113 · Ls mean difference: -0.16 · 95% CI -0.36 to 0.04
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.5811 · Ls mean difference: 0.05 · 95% CI -0.13 to 0.23
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.6794 · Ls mean difference: -0.04 · 95% CI -0.25 to 0.17
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.6031 · Ls mean difference: 0.05 · 95% CI -0.14 to 0.25
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.6673 · Ls mean difference: -0.04 · 95% CI -0.24 to 0.15
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.6472 · Ls mean difference: -0.05 · 95% CI -0.25 to 0.16
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.8654 · Ls mean difference: -0.02 · 95% CI -0.26 to 0.22
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.2101 · Ls mean difference: -0.18 · 95% CI -0.48 to 0.11
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.7128 · Ls mean difference: -0.05 · 95% CI -0.30 to 0.21
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.3297 · Ls mean difference: -0.09 · 95% CI -0.27 to 0.09
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.4493 · Ls mean difference: 0.05 · 95% CI -0.08 to 0.19
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0717 · Ls mean difference: 0.15 · 95% CI -0.01 to 0.31
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.1054 · Ls mean difference: 0.11 · 95% CI -0.02 to 0.24
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0408 · Ls mean difference: 0.18 · 95% CI 0.01 to 0.36
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0233 · Ls mean difference: 0.20 · 95% CI 0.03 to 0.38
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.3610 · Ls mean difference: 0.08 · 95% CI -0.09 to 0.26
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.2358 · Ls mean difference: 0.12 · 95% CI -0.08 to 0.32
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.9492 · Ls mean difference: 0.01 · 95% CI -0.16 to 0.17
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.4352 · Ls mean difference: -0.08 · 95% CI -0.28 to 0.12
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.1176 · Ls mean difference: 0.20 · 95% CI -0.05 to 0.44
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.7812 · Ls mean difference: 0.05 · 95% CI -0.30 to 0.40
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.5085 · Ls mean difference: -0.12 · 95% CI -0.48 to 0.24
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.8274 · Ls mean difference: 0.03 · 95% CI -0.28 to 0.34
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.3675 · Ls mean difference: -0.04 · 95% CI -0.13 to 0.05
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.1818 · Ls mean difference: -0.06 · 95% CI -0.15 to 0.03
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0826 · Ls mean difference: -0.08 · 95% CI -0.17 to 0.01
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.6436 · Ls mean difference: -0.02 · 95% CI -0.11 to 0.07
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.1827 · Ls mean difference: -0.06 · 95% CI -0.15 to 0.03
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.9859 · Ls mean difference: 0.00 · 95% CI -0.09 to 0.09
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.6672 · Ls mean difference: 0.02 · 95% CI -0.07 to 0.11
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.2031 · Ls mean difference: 0.06 · 95% CI -0.03 to 0.15
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.6664 · Ls mean difference: 0.02 · 95% CI -0.07 to 0.11
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.3417 · Ls mean difference: -0.04 · 95% CI -0.13 to 0.05
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.6622 · Ls mean difference: -0.02 · 95% CI -0.12 to 0.08
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.9087 · Ls mean difference: -0.01 · 95% CI -0.11 to 0.09
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.8263 · Ls mean difference: 0.01 · 95% CI -0.08 to 0.10
SecondaryChange From Baseline at Key Time Points in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score

The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in participants with mood disorders. It was designed as an adjunct to the HAM-D, to be more sensitive than the Hamilton Scale to the changes brought on by antidepressants and other forms of treatment. Each item yielded a score of 0 to 6. The MADRS total score was calculated as the sum of the 10 individual item scores, which ranged from 0 to 60. Higher MADRS scores indicates more severe depression. A negative change from baseline indicates less severe depression. A positive change from baseline indicates more severe depression.

Time frame:
Baseline, Hour 60, Days 7 and 30
Reported as:
Mean · score on a scale
Change From Baseline at Key Time Points in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
score on a scalePlaceboSAGE-547 90 μg/kg/h
Hour 60-15.66 ± 1.329-20.52 ± 1.333
Day 7-15.35 ± 1.658-18.91 ± 1.676
Day 30-20.52 ± 1.489-20.48 ± 1.504
Statistical analysis
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.0033 · Ls mean difference: -4.86 · 95% CI -8.06 to -1.66
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.1017 · Ls mean difference: -3.56 · 95% CI -7.84 to 0.72
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.9845 · Ls mean difference: 0.04 · 95% CI -3.72 to 3.79
SecondaryPercentage of Participants With Clinical Global Impression - Improvement (CGI-I) Response

The CGI-I response was defined as having a score of 1 (very much improved) or 2 (much improved). CGI-I item employs a 7-point Likert scale to measure the overall improvement in the participant's condition post-treatment. The investigator rated the participant's total improvement whether or not it was due entirely to drug treatment. Response choices include: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. The CGI-I was only rated at post-treatment assessments. By definition, all CGI-I assessments were evaluated against baseline conditions.

Time frame:
Hour 60, Days 7 and 30
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Response
percentage of participantsPlaceboSAGE-547 90 μg/kg/h
Hour 6055.879.6
Day 754.770.0
Day 3078.881.3
Statistical analysis
  • Placebo vs SAGE-547 90 μg/kg/h · GEE method · p = 0.0005 · Odds ratio (or): 5.0 · 95% CI 2.0 to 12.5
  • Placebo vs SAGE-547 90 μg/kg/h · GEE method · p = 0.0478 · Odds ratio (or): 2.9 · 95% CI 1.0 to 8.4
  • Placebo vs SAGE-547 90 μg/kg/h · GEE method · p = 0.4399 · Odds ratio (or): 1.5 · 95% CI 0.5 to 4.6
SecondaryChange From Baseline in the Generalized Anxiety Disorder 7-Item Scale (GAD-7) Total Score

The GAD-7 is a participant-rated, generalized anxiety symptom severity scale. Scoring for GAD-7 generalized anxiety is calculated by assigning scores of 0 = "not at all sure," 1 = "several days," 2 = "over half the days," and 3 = "nearly every day" to the response categories. The GAD-7 total score for the seven items ranges from 0 to 21, where a score of 0 to 4 = minimal anxiety, 5 to 9 = mild anxiety, 10 to 14 = moderate anxiety, and 15 to 21 = severe anxiety. The GAD-7 total score was calculated as the sum of the seven individual item scores. A negative change from baseline indicates less anxiety. A positive change from baseline indicates more anxiety.

Time frame:
Baseline, Hour 60, Days 7, 14, 21 and 30
Reported as:
Least squares mean · score on a scale
Change From Baseline in the Generalized Anxiety Disorder 7-Item Scale (GAD-7) Total Score
score on a scalePlaceboSAGE-547 90 μg/kg/h
Hour 60-6.41 ± 0.814-7.58 ± 0.850
Day 7-7.67 ± 0.858-8.43 ± 0.879
Day 14-7.90 ± 0.937-9.76 ± 0.961
Day 21-8.92 ± 1.053-10.88 ± 1.081
Day 30-9.89 ± 0.884-10.20 ± 0.913
Statistical analysis
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.2636 · Ls mean difference: -1.17 · 95% CI -3.24 to 0.90
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.4897 · Ls mean difference: -0.76 · 95% CI -2.96 to 1.43
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.1341 · Ls mean difference: -1.86 · 95% CI -4.30 to 0.59
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.1691 · Ls mean difference: -1.95 · 95% CI -4.76 to 0.85
  • Placebo vs SAGE-547 90 μg/kg/h · MMRM · p = 0.7852 · Ls mean difference: -0.31 · 95% CI -2.60 to 1.97
SecondaryPercentage of Participants With Treatment Emergent Adverse Event (TEAE)

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an AE with onset on or after the start of study drug infusion, or any worsening of a pre-existing medical condition/AE with onset on or after the start of study drug infusion.

Time frame:
Up to approximately 37 days
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment Emergent Adverse Event (TEAE)
percentage of participantsPlaceboSAGE-547 90 μg/kg/h
Percentage of Participants With Treatment Emergent Adverse Event (TEAE)45.349.0
SecondaryTime to Change in Antidepressant Medication

The time to first start or increase in the dose and time to first stop or decrease in the dose of any antidepressant medication.

Time frame:
Up to approximately 37 days
Reported as:
Median · days
Time to Change in Antidepressant Medication
daysPlaceboSAGE-547 90 μg/kg/h
Time to first start/increase in dose8 (4 to 13)10 (7 to 17)
Time to first stop/decrease in dose—18 (18 to 18)

Adverse events

Collected over Up to approximately 37 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/53 (0%)0/53 (0%)13/53 (24.5%)
SAGE-547 90 μg/kg/h0/51 (0%)1/51 (2%)21/51 (41.2%)
Most frequent serious events
Most frequent serious events
EventPlaceboSAGE-547 90 μg/kg/h
Altered state of consciousnessNervous system disorders0/531/51
SyncopeNervous system disorders0/531/51
Most frequent other events
Most frequent other events
EventPlaceboSAGE-547 90 μg/kg/h
HeadacheNervous system disorders6/539/51
NauseaGastrointestinal disorders2/535/51
Infusion site painGeneral disorders2/535/51
DizzinessNervous system disorders4/535/51
SomnolenceNervous system disorders2/534/51
FatigueGeneral disorders2/533/51

Baseline characteristics

Participants who received the study drug.

Age, Continuous
Age, Continuous(years)PlaceboSAGE-547 90 μg/kg/hTotal
Mean27.3 ± 5.9028.2 ± 6.0927.8 ± 5.98
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboSAGE-547 90 μg/kg/hTotal
Female5351104
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboSAGE-547 90 μg/kg/hTotal
Black or African American192241
White332962
Other101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboSAGE-547 90 μg/kg/hTotal
Hispanic or Latina141024
Not Hispanic or Latina394180
Hamilton Rating Scale for Depression (HAMD) Total Score
Hamilton Rating Scale for Depression (HAMD) Total Score(score on a scale)PlaceboSAGE-547 90 μg/kg/hTotal
Mean22.7 ± 1.5922.6 ± 1.5622.7 ± 1.57
08

Study locations

32 sites
  • Sage Investigational Site
    Chandler, Arizona 85226, United States
  • Sage Investigational Site
    Rogers, Arkansas 72758, United States
  • Sage Investigational Site
    Lemon Grove, California 91945, United States
  • Sage Investigational Site
    Orange, California 92868, United States
  • Sage Investigational Site
    Ventura, California 93003, United States
  • Sage Investigational Site
    Gainesville, Florida 32607, United States
  • Sage Investigational Site
    Miami, Florida 33147, United States
  • Sage Investigational Site
    Miramar, Florida 33027, United States
  • Sage Investigational Site
    Orlando, Florida 32807, United States
  • Sage Investigational Site
    Pensacola, Florida 32502, United States
  • Sage Investigational Site
    Pinellas Park, Florida 33782, United States
  • Sage Investigational Site
    Atlanta, Georgia 30331, United States
  • Sage Investigational Site
    Hoffman Estates, Illinois 60169, United States
  • Sage Investigational Site
    Wichita, Kansas 67226, United States
  • Sage Investigational Site
    Edgewood, Kentucky 41017, United States
  • Sage Investigational Site
    Owensboro, Kentucky 42303, United States
  • Sage Investigational Site
    Boston, Massachusetts 02114, United States
  • Sage Investigational Site
    Flowood, Mississippi 39232, United States
  • Sage Investigational Site
    Marlton, New Jersey 08053, United States
  • Sage Investigational Site
    Glen Oaks, New York 11004, United States
  • Sage Investigational Site
    Chapel Hill, North Carolina 27514, United States
  • Sage Investigational Site
    Charlotte, North Carolina 28211, United States
  • Sage Investigational Site
    Raleigh, North Carolina 27612, United States
  • Sage Investigational Site
    Columbus, Ohio 43210, United States
  • Sage Investigational Site
    Dayton, Ohio 45417, United States
  • Sage Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • Sage Investigational Site
    Baytown, Texas 77521, United States
  • Sage Investigational Site
    Houston, Texas 77030, United States
  • Sage Investigational Site
    Houston, Texas 77058, United States
  • Sage Investigational Site
    Richardson, Texas 75080, United States
  • Sage Investigational Site
    San Antonio, Texas 78229, United States
  • Sage Investigational Site
    Orem, Utah 84058, United States
09

References and documents

Publications

  • Gerbasi ME, Meltzer-Brody S, Acaster S, Fridman M, Bonthapally V, Hodgkins P, Kanes SJ, Eldar-Lissai A. Brexanolone in Postpartum Depression: Post Hoc Analyses to Help Inform Clinical Decision-Making. J Womens Health (Larchmt). 2021 Mar;30(3):385-392. doi: 10.1089/jwh.2020.8483. Epub 2020 Nov 12. PubMed 33181049 ↗
  • Meltzer-Brody S, Colquhoun H, Riesenberg R, Epperson CN, Deligiannidis KM, Rubinow DR, Li H, Sankoh AJ, Clemson C, Schacterle A, Jonas J, Kanes S. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet. 2018 Sep 22;392(10152):1058-1070. doi: 10.1016/S0140-6736(18)31551-4. Epub 2018 Aug 31. PubMed 30177236 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Data sharing will be consistent with the results submission policy of ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2016, a primary completion of Sep 2017 and a completion of Oct 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2019, 1 year 8 months after primary completion. A results delay was requested in Sep 2018.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2016
First posted
Oct 21, 2016
Start
Jul 2016
Primary completionActual
Sep 17, 2017
CompletionActual
Oct 11, 2017
Results delay requested
Sep 6, 2018
Results first posted
Jun 13, 2019
Last update
Sep 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02942017
Responsible party
Sponsor
First posted
Oct 21, 2016
Start date
Jul 2016
Primary completion
Sep 17, 2017
Completion
Oct 11, 2017
Results posted
Jun 13, 2019
Last update
Sep 15, 2025

Study contacts

Helen Colquhoun, MD
study director · Sage Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexanolone

Start the discussion